Author | Fernandes, Ana Paula | |
Author | Costa, Míriam Maria Silva | |
Author | Coelho, Eduardo Antônio Ferraz | |
Author | Michalick, Marilene Suzan Marques | |
Author | Freitas, Eloísa de | |
Author | Melo, Maria Norma | |
Author | Tafuri, Wagner Luiz | |
Author | Resende, Daniela de Melo | |
Author | Hermont, Vinícius | |
Author | Abrantes, Christiane de Freitas | |
Author | Gazzinelli, Ricardo Tostes | |
Access date | 2023-07-03T12:12:09Z | |
Available date | 2023-07-03T12:12:09Z | |
Document date | 2008 | |
Citation | FERNANDES, Ana Paula et al. Protective immunity against challenge with Leishmania (Leishmania) chagasi in beagle dogs vaccinated with recombinant A2 protein. Vaccine, v. 26, n. 46, p. 5888-5895, 2008. doi: 10.1016/j.vaccine.2008.05.095. | en_US |
ISSN | 0264-410X | en_US |
URI | https://www.arca.fiocruz.br/handle/icict/59354 | |
Language | eng | en_US |
Publisher | Elsevier Science | en_US |
Rights | restricted access | en_US |
Title | Protective immunity against challenge with Leishmania (Leishmania) chagasi in beagle dogs vaccinated with recombinant A2 protein | en_US |
Type | Article | en_US |
DOI | 10.1016/j.vaccine.2008.05.095 | |
Abstract | In this study, we investigated in dogs the immunogenicity and protective immunity against Leishmania (Leishmania) chagasi infection induced by vaccination with a formulation containing the recombinant A2 protein, an amastigote specific antigen, and saponin. Vaccinated animals produced significantly increased levels of total IgG and IgG2, but not lgG1 anti-A2 antibodies, and remained negative in conventional leishmaniasis serodiagnostic methods. Significantly increased IFN-gamma and low IL-10 levels were detected in vaccinated animals before and after challenge, as compared to control animals. Importantly, while the symptoms onset appeared as early as three months after infection in most control dogs, 14 months after challenge, 5 out of 7 vaccinated dogs remained asymptomatic. Therefore, immunization with rA2 antigen was immunogenic and induced partial protection in dogs, and allowed the serological differentiation between vaccinated and infected animals, an important requirement for a canine visceral leishmaniasis (CVL) vaccine. | en_US |
Affilliation | Department of Clinical and Toxicological Analysis. School of Pharmacy. Federal University of Minas Gerais. Belo Horizonte, MG, Brazil | en_US |
Affilliation | Department of Biochemistry and Immunology. Institute of Biological Sciences. Federal University of Minas Gerais. Belo Horizonte, MG, Brazil | en_US |
Affilliation | Department of Biochemistry and Immunology. Institute of Biological Sciences. Federal University of Minas Gerais. Belo Horizonte, MG, Brazil | en_US |
Affilliation | Department of Parasitology. Institute of Biological Sciences. Federal University of Minas Gerais. Belo Horizonte, MG, Brazil | en_US |
Affilliation | Department of Parasitology. Institute of Biological Sciences. Federal University of Minas Gerais. Belo Horizonte, MG, Brazil | en_US |
Affilliation | Department of Parasitology. Institute of Biological Sciences. Federal University of Minas Gerais. Belo Horizonte, MG, Brazil | en_US |
Affilliation | Department of Pathology. Institute of Biological Sciences. Federal University of Minas Gerais. Belo Horizonte, MG, Brazil | en_US |
Affilliation | Department of Biochemistry and Immunology. Institute of Biological Sciences. Federal University of Minas Gerais. Belo Horizonte, MG, Brazil | en_US |
Affilliation | Hertape-Calier Saúde Animal. Juatuba, MG, Brazil | en_US |
Affilliation | Hertape-Calier Saúde Animal. Juatuba, MG, Brazil | en_US |
Affilliation | Department of Biochemistry and Immunology. Institute of Biological Sciences. Federal University of Minas Gerais. Belo Horizonte, MG, Brazil/René Rachou Institute. Oswaldo Cruz Foundation. Belo Horizonte, MG, Brazil/Department of Medicine. University of Massachusetts Medical School. Worcester, MA, USA | en_US |
Subject | Canine visceral leishmaniasis | en_US |
Subject | Recombinant vaccine | en_US |
Subject | A2 antigen | en_US |
Embargo date | 2099-12-31 | |